Invitrogen, Celera Genomics, Seattle Genetics, Vivascience, Power3 Medical Products, Syrrx, NIGMS, European Commission | GenomeWeb

Invitrogen Revenues and Earnings Up in Q2

Invitrogen’s revenues and earnings increased for the second quarter, the company reported this week.

Revenues increased approximately 32 percent to $254 million, compared to $192.4 million during the second quarter of 2003.

Invitrogen said the revenue growth included a 19 percent increase in its BioDiscovery unit, which is due principally to its Molecular Probes acquisition.

Research and development costs increased to $18.2 million, from $12.6 mllion during the same quarter last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.